Clinical trials: Tocilizumab
B-cell Non-Hodgkin Lymphoma
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of intravenous (IV) or subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large…
- Trial name
- NCT03671018
- Testing
- Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 422 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis
The primary objective of this study is: To assess the efficacy and safety of dose regimens of ALX-0061 monotherapy administered subcutaneously (s.c.) to subjects with active rheumatoid arthritis (RA).
- Trial name
- NCT02287922
- Testing
- ALX-0061, Tocilizumab
- Where
- 83 sites in United States, Belgium and 12 more
- Volunteers
- 251 people
- Sponsor
- Ablynx, a Sanofi company
Healthy Volunteer
A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers
This Phase IV, single-blind , randomized, two-arm study will explore the pharmacodynamics effects of RoActemra/Actemra (tocilizumab) on neutrophil redistribution, function and survival in healthy subjects.
- Trial name
- NCT01991990
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Cutaneous Melanoma, Uveal Melanoma
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC)…
- Conditions
- Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
- Trial name
- NCT04551352
- Testing
- RO7293583, Tocilizumab, Obinutuzumab
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis
This multicenter, open-label, single arm long-term extension of study WA19926 will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with early, moderate to severe rheumatoid arthritis who have…
- Trial name
- NCT01665430
- Testing
- Tocilizumab
- Where
- 4 sites in Poland
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis.
- Trial name
- NCT01649804
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Hungary
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis
This single arm, open label study will assess the safety and efficacy, with regard to reduction of signs and symptoms,of treatment with tocilizumab in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT00848120
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 4 sites in Philippines
- Volunteers
- 29 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment
This open-label, single-arm study will evaluate the efficacy, safety and tolerability of subcutaneously administered tocilizumab in monotherapy and/or in combination with methotrexate and other non-biologic disease modifying…
- Trial name
- NCT02031471
- Testing
- tocilizumab
- Where
- 17 sites in Belgium, Luxembourg
- Volunteers
- 57 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with…
- Trial name
- NCT02165345
- Testing
- Tocilizumab
- Where
- 31 sites in United States, Argentina and 10 more
- Volunteers
- 82 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin".
- Trial name
- SELECT-sJIA (NCT05609630)
- Testing
- Upadacitinib, Tocilizumab
- Where
- 45 sites in United States, Argentina and 15 more
- Volunteers
- 90 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis
This multi-center, open-label single arm Phase IIIb study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab administered as monotherapy and/or in combination with methotrexate or other non-biologic disease…
- Trial name
- OSCAR (NCT01987479)
- Testing
- Non-Biologic DMARDs, Tocilizumab, Methotrexate
- Where
- 20 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a…
- Trial name
- NCT01089023
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in Bahrain, Iran and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to evaluate the pharmacokinetics, safety and immunogenicity of BAT1806 Injection vs Actemra® (EU-licensed and US-licensed) in healthy Chinese male…
- Trial name
- NCT03606876
- Testing
- BAT1806 injection
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Bio-Thera Solutions
Rheumatoid Arthritis
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and immunogenicity of CDP6038 treatment in adult subjects with active rheumatoid arthritis who have had an inadequate response to anti-tumor…
- Trial name
- NCT01242488
- Testing
- CDP6038, Tocilizumab (Actemra or RoActemra)
- Where
- 82 sites in United States, Belgium and 1 more
- Volunteers
- 221 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This prospective, multi-center, observational study will assess the efficacy and safety of treatment in patients who are treated with a TNF Inhibitor or RoActemra/Actemra (tocilizumab) as the first biologic therapy.
- Trial name
- NCT01543503
- Where
- 154 sites in Argentina, Belgium and 14 more
- Volunteers
- 1,225 people
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Active Rheumatoid Arthritis
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis
This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of intravenous HS628 in combination with MTX versus Actemra in combination with MTX, in participants with moderate to…
- Trial name
- NCT06048224
- Testing
- HS628+MTX, Actemra +MTX
- Where
- China
- Volunteers
- 669 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Rheumatoid Arthritis
An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis
This open-label, single arm, multicenter long-term extension study of WA19926 evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with moderate to severe rheumatoid arthritis who completed the…
- Trial name
- NCT01664598
- Testing
- Tocilizumab
- Where
- 12 sites in Russia
- Volunteers
- 49 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes Mellitus
VV-14300 for the Treatment of Type 1 Diabetes
This study is testing VV-14300 in adults with long-standing type 1 diabetes (T1D) whose blood sugar is not well controlled despite using an automated insulin delivery (AID) system.
- Trial name
- RELIEVE (NCT07831798)
- Testing
- VV-14300
- Where
- 2 sites in Canada, New Zealand
- Volunteers
- 29 people
- Sponsor
- Kriya Therapeutics, Inc.
Diffuse Large B-cell Lymphoma
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease…
- Trial name
- NCT03677154
- Testing
- Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin
- Where
- 32 sites in United States, Israel and 4 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP
This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.
- Trial name
- NCT00144586
- Testing
- MRA(Tocilizumab)
- Volunteers
- 42 people
- Sponsor
- Chugai Pharmaceutical